For example, the peptide vaccine oxidized-mannan-MUC1 showed a significantly reduced recurrence rate in the verum versus the placebo group (12.5% vs. 60.0%) among patients with stage II breast cancer in a pilot phase III study with a long-term follow-up of up to 15 years [38]. This evidence concerns the gene MUC1 and breast cancer.